Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Rheumatology Gastroenterology Diabetes / Metabolic Women's Health Mental Health / Psychiatry Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06887387

Wearable Devices for Patient Monitoring in Long QT Syndrome

Wearable Devices for Patient Monitoring in Long QT Syndrome — Recruiting • Cardiology / Cardiovascular • NCT06887387.

📅 19 May 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06887387
Sponsor
Queen Mary University of London
Start
2025-04-01
ClinicaliQ Trial Snapshot
  • Wearable Devices for Patient Monitoring in Long QT Syndrome — Recruiting • Cardiology / Cardiovascular • NCT06887387.
  • What is being tested: Utility of wearable devices for continuous patient monitoring in Long QT syndrome, a rare inherited cardiac arrhythmia disorder characterised by prolonged ventricular repolarisation and risk of sudden cardiac death.
  • Patient eligibility overview: The study targets patients with confirmed Long QT syndrome diagnosis, likely including both symptomatic individuals and asymptomatic carriers, across various age groups and disease severity profiles.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The main research question of this study is whether wearable devices have utility in monitoring patients with Long QT syndrome.

Eligibility Snapshot
  • : * Clinical diagnosis of Long QT Syndrome * Aged 18 years or over * Phone with iOS version 15 or Android OS 9.0 or higher * Able and willing to provide informed consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
Cardiology / Cardiovascular · 30 Mar 2026
Covers risk stratification for sudden cardiac death and indications for ICD implantation • Provides management recommendations for ventricular tachycardia and ventricular fibrillation…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Cardiology / Cardiovascular · 30 Mar 2026
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies…
View guideline →
Guideline
Heart Failure: Diagnosis and Management (NICE NG106)
Cardiology / Cardiovascular · 27 Mar 2026
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →